Cohn Aaron D, Quiram Polly A, Drenser Kimberly A, Trese Michael T, Capone Antonio
Beaumont Eye Institute, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
Retina. 2009 Jun;29(6):825-30. doi: 10.1097/IAE.0b013e31819b1788.
To determine the surgical outcomes of epiretinal membranes associated with combined hamartoma of the retina and retinal pigment epithelium after pars plana vitrectomy and membrane peeling with or without assistance of autologous plasmin enzyme.
Retrospective review of 11 pediatric eyes that underwent pars plana vitrectomy with membrane peeling with or without autologous plasmin enzyme. Preoperative and postoperative assessments of visual function and retinal architecture were performed by indirect ophthalmoscopy, optical coherence tomography imaging, fundus photography, and measurement of visual acuity.
The mean age of the patients was 4.6 years (range, 1-14). Mean follow-up was 15.6 months (range, 6-42 months). The lesions were located solely in the macula in 8 of 11 (73%) patients and in the macula and posterior pole in 3 of 11 (27%) patients. Of the 11 eyes, 6 were preoperatively injected with autologous plasmin enzyme to assist in removal of the posterior hyaloid. All 11 patients (100%) had complete macular reattachment postoperatively. Eight of 11 (73%) showed improved visual acuity postoperatively, and 3 of 11 showed stabilized vision. Eight eyes required only one surgery. Four eyes (36.6%) had recurrences of epiretinal membrane, and three of these eyes required additional surgery. Of the eyes with preoperative plasmin injection, 4 of 6 (66%) showed an improvement in visual acuity whereas 2 of 6 (33%) showed stabilization of visual acuity. Four of five without plasmin showed visual improvement, and one of five had stabilization of vision.
In the pediatric population, pars plana vitrectomy with membrane peeling with or without the use of autologous plasmin enzyme for epiretinal membrane associated with combined hamartomas of the retina and retinal pigment epithelium can result in improved retinal architecture and visual acuity. Visual acuity may improve despite recurrence of the epiretinal membrane.
确定在玻璃体切割联合视网膜及视网膜色素上皮错构瘤的视网膜前膜剥除术中,使用或不使用自体纤溶酶辅助手术的效果。
回顾性分析11例接受了玻璃体切割联合视网膜前膜剥除术的小儿患者,术中使用或未使用自体纤溶酶。术前及术后通过间接检眼镜、光学相干断层扫描成像、眼底照相及视力测量对视觉功能和视网膜结构进行评估。
患者的平均年龄为4.6岁(范围1 - 14岁)。平均随访时间为15.6个月(范围6 - 42个月)。11例患者中,8例(73%)的病变仅位于黄斑区,3例(27%)的病变位于黄斑区和后极部。11只眼中,6只眼术前注射了自体纤溶酶以辅助去除后玻璃体。所有11例患者(100%)术后黄斑均完全复位。11例中有8例(73%)术后视力提高,3例视力稳定。8只眼仅需一次手术。4只眼(36.6%)视网膜前膜复发,其中3只眼需要再次手术。术前注射纤溶酶的眼中,6只中有4只(66%)视力提高,2只(33%)视力稳定。未注射纤溶酶的5只眼中,4只视力改善,1只视力稳定。
在小儿患者中,对于与视网膜及视网膜色素上皮错构瘤相关的视网膜前膜,采用玻璃体切割联合视网膜前膜剥除术,无论是否使用自体纤溶酶,均可改善视网膜结构和视力。即使视网膜前膜复发,视力仍可能提高。